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MicroRNAs (miRNAs) are known to be important post-transcriptional regulators that are
involved in the etiology of complex psychiatric traits. The present study aimed to incorpo-
rate miRNAs information into pathway analysis using a genome-wide association dataset
to identify relevant biological pathways for bipolar disorder (BPD). We selected psychiatric-
and neurological-associated miRNAs (N =157) from PhenomiR database. The miRNA tar-
get genes (miTG) predictions were obtained from microRNA.org. Canonical pathways
(N =4,051) were downloaded from the Molecule Signature Database. We employed a
novel weighting scheme for miTGs in pathway analysis using methods of gene set enrich-
ment analysis and sum-statistic. Under four statistical scenarios, 38 significantly enriched
pathways (P -value<0.01 after multiple testing correction) were identified for the risk of
developing BPD, including pathways of ion channels associated (e.g., gated channel activity,
ion transmembrane transporter activity, and ion channel activity) and nervous related bio-
logical processes (e.g., nervous system development, cytoskeleton, and neuroactive ligand
receptor interaction). Among them, 19 were identified only when the weighting scheme
was applied. Many miRNA-targeted genes were functionally related to ion channels, col-
lagen, and axonal growth and guidance that have been suggested to be associated with
BPD previously. Some of these genes are linked to the regulation of miRNA machinery in
the literature. Our findings provide support for the potential involvement of miRNAs in the
psychopathology of BPD. Further investigations to elucidate the functions and mechanisms
of identified candidate pathways are needed.
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INTRODUCTION
Bipolar disorder (BPD) is a highly heritable psychiatric illness.
The genetic components were estimated to account for as high as
∼80% of phenotypic variability (McGuffin et al., 2003). Although
many candidate and genome-wide association (GWA) studies have
conducted to investigate the complex nature of pathogenetics in
BPD, previously reported genetic findings only account for a small
proportion of its heritability (Gershon et al., 2011). The missing
heritability may be partially explained by the limited numbers,
types, and frequency of susceptible variants that currently geno-
typed in high-throughput array, and other mechanisms such as
gene× gene or gene× environment interactions, as well as the
heterogeneity in phenotype definitions across studies (Manolio
et al., 2009). Nevertheless, large-scale GWA studies remain to be an
efficient and promising study design to uncover the underlying eti-
ology of complex psychiatric disorders (Sullivan and Investigators,
2012), while new theoretical framework and statistical approaches
must be taken into consideration.
Recently, pathway-based analysis, which simultaneously tests a
group of functionally related genes, has been widely used as an
alternative and complementary strategy to bring more insights
into the biological mechanisms of disease of interest (Wang et al.,
2010). In addition, inclusion of prior information from other
aspects, such as gene expression or gene regulation in GWAS
analysis offers great opportunities to identify new association find-
ings and to generate novel hypotheses (Tintle et al., 2009a). For
instance, two prior GWA studies in type 2 diabetes and osteo-
porosis applied integrative approaches that used gene expression
data and pathway-based analysis to identify novel associated path-
ways and loci (Hsu et al., 2010; Zhong et al., 2010). In addition
to gene expression information, other types of data could also be
incorporated into pathway-based analysis using GWA data, such
as methylation (Chuang et al., 2012) and microRNAs (miRNAs)
patterns, especially disease-associated miRNAs.
The miRNAs are one kind of functional non-coding RNAs
acting as post-transcriptional regulators for translation and the
stability of mRNAs, which involved in a wide range of biological
processes, including regulation of brain and neuronal develop-
ment (Fiore et al., 2008). The miRNA dysregulation has been
reported to play important roles in the etiology of many dis-
eases, including complex psychiatric traits (Xu et al., 2010). Pre-
viously, many psychiatric- and neurological-associated miRNAs
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were identified from expression studies of postmortem brain and
animal models (Forero et al., 2010), and from genetic association
studies of variants in genes encoding miRNAs and binding site
of miRNAs target genes (Muinos-Gimeno et al., 2009; The Schiz-
ophrenia Psychiatric Genome-Wide Association Study (GWAS)
Consortium, 2011).
We have known that an individual miRNA could target hun-
dreds of mRNA molecules (Lim et al., 2005), therefore the target
genes of a phenotype-related miRNA may potentially associate
with the trait. For example, abnormal expression level of brain-
expressed miR-132 has been reported to be associated with psy-
chiatric disorders via affecting the expression of brain-derived
neurotrophic factor that is involved in dendritic plasticity (Klein
et al., 2007; Wayman et al., 2008; Askland et al., 2009; Forero et al.,
2010). In addition, different psychiatric disorders (e.g., schizo-
phrenia and BPD) may share some degree of the genetic factors
through the involvement of similar biological pathways. Thus, a
single miRNA may play roles in the etiology of more than one
psychiatric disorder. Given these features of miRNAs, it is our
interest to incorporate information of phenotype-related miRNAs
and their predicted targets into the GWA analysis, which provide
a new avenue for researchers to investigate the underlying genetic
components that are associated with BPD.
In the current study, we performed pathway-based analy-
sis using large-scale GWA dataset of BPD in combination with
the data source of miRNAs. The psychiatric- and neurological-
associated miRNAs were identified from PhenomiR database and
miRNA target predictions were obtained from microRNA.org
database. Our main goal is to better identify genes and important
biological pathways to be associated with BPD while incorporating
the regulatory information of miRNAs.
MATERIALS AND METHODS
Figure 1 shows the data integration flowchart in our study to
identify the psychiatric- and neurological-associated miRNAs and
their target genes, and the annotated pathways for pathway-based
analysis. Details are mentioned below.
GENOME-WIDE ASSOCIATION DATASET
The Genetic Association Information Network (GAIN) GWA
dataset was downloaded from dbGaP1. We extracted BPD dataset
from the GAIN: full details of subject enrollment and genotyping
can be obtained in the original article (The GAIN Collaborative
Research Group, 2007). The GWA dataset of BPD comprised 1,001
BPD cases and 1,034 controls, which used Affymetrix Genome-
Wide Human SNP Array 6.0 platform for SNP (single nucleotide
polymorphism) genotyping. After applying quality control filters
and excluding SNPs in sexual chromosomes, there were 698,227
autosomal SNPs in the GWA dataset in our analyses.
IDENTIFICATION OF TARGET GENES OF PSYCHIATRIC
DISEASE-ASSOCIATED miRNAs
Information of disease-associated miRNAs was downloaded from
the PhenomiR database (Ruepp et al., 2010). The PhenomiR
1http://www.ncbi.nlm.nih.gov/gap
collected published miRNA-disease associations via manual cura-
tion. It annotates diseases into 22 classes according to the Online
Mendelian Inheritance in Man (OMIM) Morbid Map. In our
analysis, we selected all miRNAs that are associated with neurolog-
ical and psychiatric classes as the candidates of disease-associated
miRNAs. In total, there were 157 unique miRNAs to form 293
miRNA-disease association pairs.
The miRNA target predictions were obtained from micor-
RNA.org database2 (Betel et al., 2008). The microRNA.org per-
formed miRNA target prediction using miRanda algorithm (John
et al., 2004) and scored the likelihood of mRNA downregulation
of predicted target sites by using mirSVR algorithm (Betel et al.,
2010). The combination of miRanda-mirSVR approach has been
shown to effectively identify target predictions to cover a signifi-
cant number of non-canonical sites, and has competitive ability in
predicting expression changes of mRNA or proteins when com-
paring with other target prediction methods (Betel et al., 2010).
In total, 1,097,064 “good mirSVR score-conserved miRNA” tar-
get predictions were used in this procedure. Combining these
two datasets while follows the criteria of alignment score ≥140,
seed site ≥6, free energy ≤−17, and conservation score ≥0.57
(Figure 1), we identified 8,921 genes which were predicted to be
the targets of psychiatric- and neurological-associated miRNAs.
We also used another miRNA target prediction algorithm,
DIANA-microT, which considers not only strong binding (at least
seven consecutive Watson-Crick base pairing nucleotides) but also
weak binding ability (only six paired nucleotides or G:U wobble
pairs) to predict the miRNA target genes (miTG; Maragkakis et al.,
2009a,b). DIANA-microT provides scores for miTG as an indica-
tor for the probability of being a real target site. The calculation of
an overall miTG score mainly based on scoring all binding types
and conservation profile of all putative miRNA recognition ele-
ment (MRE) within the 3′UTR using the weighted sum method.
Therefore, target genes of psychiatric- and neurological-associated
miRNAs with high predictive probability in significant pathways
were filtered by the DIANA-microT algorithm. We used a miTG
score greater than 19 (a strict threshold) as the selection criterion,
which implicates the predicted target was highly reliable being a
true miRNA target.
STATISTICAL ANALYSIS
We used PLINK (version 1.07) to conduct single marker associ-
ation analyses with additive model (Purcell et al., 2007). We first
mapped SNPs to genes to obtain gene-level statistic for BPD using
the GWA dataset in GAIN. SNPs were mapped to genes if they
located within 5 kb of the 5′ upstream and 3′ downstream of a gene
using NCBI human genome build 36. For each gene, the smallest
P-value (Pmin) among all SNPs within the gene region was used to
represent the gene-level statistic. In total, there were 304,343 SNPs
assigned into 16,385 genes in the GWA dataset of BPD.
Annotated pathways were obtained from the Molecule Sig-
nature Database, MsigDB (Subramanian et al., 2005). MsigDB
consists of several online pathway databases, including Kyoto
Encyclopedia of Genes and Genomes (KEGG), BioCarta, Reac-
tome, Gene Ontology (GO) terms, and gene sets collected from
2http://www.microrna.org/microrna/home.do
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Alignment score ≥140 
Seed site ≥6 
Free energy ≤-17 
Conservation score ≥0.57 
Psychiatric- and neurological-associated 
miRNAs from PhenomiR database 
157 miRNAs 




miRNA target genes 
8921 genes 
(36,278 predictions) 
GAIN GWAS dataset 
698,227 SNPs 




Pathway information (10-380 
genes per set) 
4,051 pathways 
Pathway analysis 
FIGURE 1 |The flowchart of identification of psychiatric- and neurological-associated miRNAs and their target genes and information for pathway
analysis.
published literature. From MsigDB, we obtained 4,726 pathways
that cover 22,429 genes. Pathways containing less than 10 genes or
more than 380 genes were excluded to avoid bias due to extreme
small or large pathway size. Thus, there were 4,051 canonical path-
ways in the pathway-based analyses using the GWA dataset of BPD
in the present study.
Pathway-based analyses were conducted using both competi-
tive and self-contained approaches (Wang et al., 2010) to capture
a broader range of important pathways. The gene set enrichment
analysis (GSEA), as a competitive method, first ranks Pmin values
of all genes from the smallest to the largest. Then, for a given path-
way, an enrichment score (ES) was calculated based on gene-wise
statistic values (t j), which were defined as the χ2 statistic of the
corresponding most significant SNP to evaluate association signals
(Wang et al., 2007). The sum-statistic (SUM) approach, as a self-
contained test, sums up gene-wise statistic values (t i) over the set
of genes (ΣSi=1ti) in a specific pathway (Tintle et al., 2009b). The
details of calculation procedures were provided in our previous
study (Kao et al., 2012).
WEIGHTING PROCEDURE
We employed a weighting scheme for genes that were predicted
to be psychiatric- and neurological-associated miRNA targets in
every annotated pathway. First, we calculated the overall propor-
tion of SNPs with P-value <0.05 in the whole GAIN dataset.
Second, in a given gene, the proportion of significant SNPs was
calculated and then compared with the proportion of significant
SNPs in the whole GWA dataset to evaluate whether this gene was
informative. The detail of weighting procedures was described as
below. For each pathway, n and m represent the number of miTGs
and non- miTGs, respectively. K n and Km were the number of
informative genes in the n miTGs and m non-miTGs, respectively.
Therefore, the proportion of informative genes in the miTGs and
non-miTGs were K n/n and Km/m. The Harmonic average (H),
defined as 1/[(1/mK n)+ (1/nKm)], was used as the basis of our
weighting scheme for calculating the gene-wise weights of the
miRNA and non-miTGs in a pathway and to minimize the poten-
tial bias in the pathway analysis due to the variation of pathway
size. If K n/n was greater than Km/m, the weights for miTGs and
non-miTGs were assigned mkn/H and nkm/H, respectively. If no
informative genes exist in non-miRNA genes, a weight one was
assigned to non-miRNA genes; while a weight, ranging from one
to six, according to the proportion of informative genes (using
0.1, 0.3, 0.5, 0.7, and 0.9 as cut-off values), was assigned to miRNA
genes. Otherwise, equal weights were used for the two sets of genes.
For each pathway, weights were assigned to miTGs and non-
miTGs. Then all genes were classified into S set and NS set accord-
ing to their involvement in a pathway or not. When using compet-
itive methods, genes within a pathway were compared with genes
not within the pathway. Regarding to self-contained methods, only
genes within the pathway were considered. A total of 5,000 per-
mutations were performed to evaluate the empirical significance
level of each pathway. To account for multiple testing issues in the
analyses, algorithm proposed by Benjamini and Hochberg (1995)
was used to control for false discovery rate (FDR).
RESULTS
A total of 4,051 pathways were constructed and tested for asso-
ciations with the risk of BPD using the GWA dataset of BPD.
With the inclusion of 157 psychiatric- and neurological-associated
miRNAs as the prior information into pathway-based analyses, we
identified many enriched pathways for BPD. Under four testing
scenarios, including weighted and non-weighted GSEA and SUM
statistics, there were more than 100 significant pathways associated
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with BPD at the level of empirical P-value< 0.01, and the num-
ber was reduced to more than 40 after FDR correction (Table A1
in Appendix). Comparing with non-weighting scenario, pathway
analysis under the weighting scenario identified additional 20
and 223 significant pathways (FDR< 0.01) by using GSEA and
SUM methods, respectively (Table A2 in Appendix). Under the
non-weighted scheme, the number of enriched pathways identi-
fied by both the GSEA and SUM methods with FDR< 0.01 was
43, while the number was 38 under the weighted scheme. The
union set of these enriched pathways were in total 62 pathways
(Table A3 in Appendix), including 18 annotated GO, 7 KEGG,
and 37 curated gene sets. Among these pathways, 19 significant
pathways were identified by both the GSEA and SUM methods
using both non-weighted and weighted scheme.
Table 1 showed 19 enriched pathways with stringent criterion of
FDR< 0.01, including four GO gene sets and 15 curated gene sets,
which exhibited strong associations with BPD under all four sta-
tistical scenarios. The three significant GO gene sets, cation trans-
membrane transporter activity, gated channel activity, and ion
transmembrane transporter activity, were ion channel/transporter
related. The fourth GO gene set was nervous system develop-
ment, which was reported to be associated with BPD previously.
After performing our weighting scheme, 19 additional pathways
were identified at the significance level of FDR< 0.01 (Table 2),
including six annotated GO, 3 KEGG, and 10 curated gene sets.
Many of them are novel findings for BPD, such as cytoskeleton,
retinol metabolism, drug metabolism other enzymes, etc. In total,
we found 38 significant enriched pathways for BPD.
miRNA TARGET PREDICTION
The results of miRNA target predictions in 38 enriched path-
ways were further examined. Initially, miRNA target prediction
was performed by using miRanda-mirSVR approach with pre-
viously described filtering criteria (Figure 1). There were 2,438
unique genes in 38 significantly enriched pathways. Among them,
546 had Pmin-value less than 0.01. Table 3 summarized the results
of miRNA target predictions for these 546 genes. On average,
34.4% of the predicted miTGs had Pmin-value less than 0.01 in
enriched pathways, indicating a higher probability of showing
associations with BPD. As expected, the larger the numbers of
genes or the numbers of miTGs in a pathway, the higher number
of miRanda-mirSVR prediction was observed (correlation coeffi-
cient= 0.74 and 0.82, respectively) in the 38 enriched pathways.
We then applied the second prediction algorithm, DIANA-microT,
to increase the stringency of target genes prediction. These results
were also shown in Table 3. By using the strict threshold at miTG
score 19, we filtered out the predictions with less probability of cor-
rect prediction. Among the 38 pathways, as high as 88.9% of the
miRanda-mirSVR predictions could be also predicted by DIANA-
microT (ranged from 36.8 to 88.9%). The numbers of miRNA
target predictions were also reduced (from 0 to 28). In total, there
were 469 miRNA target predictions with miTG score >19 for
genes with Pmin-value of target gene <0.01, which consisted of
113 unique genes and 45 miRNAs. Among these predictions, 22
miTGs were involved in more than three enriched pathways. The
22 miTGs and their corresponding associated miRNAs are dis-
played in Table 4. The functions of these genes are mainly related
to potassium and calcium ion channels (e.g., KCNMA1, KCNQ5,
KCNK2,PKD2, andRYR3), collagen (e.g.,COL1A2,COL27A1, and
COL5A1), and axon guidance (e.g., NF1B, NAV3, and PTPRD).
DISCUSSION
Analyzing GWA dataset with pathway-based approach utilizes
information of multiple loci with similar physiological functions
to bring biological insights into the mechanisms of BPD (Torka-
mani et al., 2008; Askland et al., 2009; Holmans et al., 2009; Peng
et al., 2010). Integrating other data sources into the analysis frame-
work further offers more opportunities in identifying disease-
associated loci (Wang et al., 2010). The current study especially
focuses on information obtained from miRNAs, which are essen-
tial in the regulation processes of brain and neuronal development.
We performed pathway-based analyses using a GWA dataset of
BPD while incorporating the disease-associated miRNA infor-
mation into analysis. Many important pathways were identified
through our analysis framework.
First, four enriched GO terms were identified for BPD, includ-
ing cation transmembrane transporter activity, gated channel
activity, ion transmembrane transporter activity, and nervous sys-
tem development. Three of them are ion channel/transporter
related. Adding the weighting scheme by miRNA information,
we further identified two channel-related pathways (Table 2),
ion channel activity and substrate specific channel activity. The
involvement of ion channels in the etiology of BPD was also
implicated in other studies for BPD (Askland et al., 2009). We
have known that ion channels and transporters are essential com-
ponents in regulating neuronal excitability. Abnormality of ion
channels has been suggested to be a plausible mechanism under-
lying BPD. To explain the recurrence and cycling nature of mood
episodes in BPD, a kindling model was proposed as these clini-
cal conditions are the consequences of neuronal hyperexcitability,
which is linked to abnormal functions of ion channels (Mazza
et al., 2007; Blumenfeld et al., 2009). Similarly, results in recent
GWA and gene expression studies also support the involvement
of ion channel genes in the etiology of BPD (Sklar et al., 2008,
2011; Smolin et al., 2012). Thus, genes in the ion channels or
their regulatory loci have been attractive candidates in studying
the underlying mechanism for BPD. Our miTGs prediction grants
further support for this line of evidence.
In our identified 38 significantly enriched pathways, many
miTGs were functionally related to ion channels, especially for
potassium (e.g., KCNMA1, KCNQ5, and KCNK2) and calcium
(e.g., RYR3 and PKD2) channels. All these genes involved in
multiple significant pathways. For instance,KCNMA1 is a calcium-
activated potassium channel and KCNQ5 belongs to the voltage-
gated delayed rectifier potassium channel gene family. Both of
them play important roles in the regulation of neuronal excitability
(Laumonnier et al., 2006; Brown and Passmore, 2009). Molecular
and functional studies found that defects of KCNMA1 contribute
to autism and mental retardation (Laumonnier et al., 2006). For
KCNK2 gene that encodes for a two-pore-domain background
potassium channel, a recent genetic study revealed its association
with susceptibility of major depressive disorder and response to
antidepressant treatment (Liou et al., 2009). Additionally, several
susceptible genes that cause abnormality in calcium signaling,
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Genes with Pmin <0.01








ALL PATHWAY FDRBH <0.01
Cation transmembrane transporter activity 211 109 32 49 87 5
Gated channel activity 121 55 20 41 56 5
Ion transmembrane transporter activity 275 128 36 49 100 6
Nervous system development 382 191 63 70 278 28
Acevedo liver cancer with H3K27ME3 up 295 109 42 76 173 26
Acevedo liver cancer with H3K9ME3 up 141 50 19 49 72 7
Bertucci medullary vs. ductal breast cancer DN 177 88 33 64 111 15
Dacosta UV response via ERCC3 TTD DN 76 50 24 56 105 26
Hamai apoptosis via trail up 334 176 41 68 159 9
Lindgren bladder cancer cluster 3 DN 223 98 32 57 117 17
Manalo hypoxia up 211 123 37 65 123 10
Martinez response to trabectedin 42 26 15 38 52 8
Riggi ewing sarcoma progenitor up 429 222 69 83 290 21
Siligan bound by ews FLT1 fusion 36 18 14 47 68 16
Vecchi gastric cancer early DN 394 161 47 69 169 10
Verhaak AML with NPM1 mutated DN 266 130 35 62 119 2
Wang SMARCE1 targets up 170 92 29 54 99 17
Onder CDH1 signaling via CTNNB1 85 45 13 37 47 11
Sabates colorectal adenoma DN 292 118 38 62 130 12
GSEA-WEIGHTED FDRBH <0.01 AND SUM-WEIGHTED FDRBH <0.01
Synaptic transmission 172 77 26 61 126 8
Neurological system process 377 139 49 69 225 12
Ion channel activity 147 70 22 42 65 5
Substrate specific channel activity 154 74 22 42 65 5
Transmission of nerve impulse 187 83 28 61 128 8
Cytoskeleton 361 173 36 68 160 7
Neuroactive ligand receptor interaction 272 94 28 58 112 2
Retinol metabolism 64 19 12 11 19 3
Drug metabolism other enzymes 51 20 13 11 20 0
Hatada methylated in lung cancer up 367 161 41 67 120 22
Delys thyroid cancer dn 214 109 42 67 168 20
Horiuchi wtap targets up 323 147 48 73 213 23
Thum systolic heart failure dn 248 136 41 77 192 12
Iwanaga carcinogenesis by kras pten DN 445 161 39 65 133 28
Doane response to androgen dn 248 119 29 53 101 7
Foster inflammatory response LPS DN 486 219 43 73 169 22
Acevedo liver cancer with H3K27ME3 DN 226 73 20 51 102 18
Boylan multiple myeloma C D DN 328 100 23 54 83 8
Yauch hedgehog signaling Paracrine DN 385 104 30 60 123 8
*DIANA-microT algorithm was applied to the predictions obtained by using miRanda-mirSVR approach with miTG score>19 (the prediction score of a miRNA and its
trarget gene calculated by DIANA-microT algorithm).
such as CACNA1C and Bcl-2, were reported to be associated
with BPD (Sklar et al., 2008, 2011; Distelhorst and Bootman,
2011). RYR3, a brain-specific ryanodine receptor for controlling
intracellular calcium concentration, was found to be a susceptible
gene for schizophrenia (Leonard and Freedman, 2006). In addi-
tion, the RYR3 knockout mice exhibited some abnormal behaviors,
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including hyperlocomoter activity and decreased social interaction
(Matsuo et al., 2009). Although how these behaviors defects and
functional defects of ion channels link with the pathology of BPD
are still unclear, it warrants to conduct further basic and functional
research to investigate the roles of ion channels in BPD.
Second, applying the weighting scheme for psychiatric- and
neurological-associated miRNAs in the analysis, we identified sev-
eral significant pathways for BPD that were involved many nervous
related biological processes in Table 2 (Li et al., 2005; Nakatani
et al., 2006; Ryan et al., 2006; Bremner and McCaffery, 2008;
Ramocki and Zoghbi, 2008; Torkamani et al., 2008; Askland et al.,
2009). Some pathways are novel findings for BPD but show their
biological plausibility to neurological disorders in general, such
as retinol metabolism (Maden, 2002), while other pathways are
novel findings specific to BPD (not reported in other neurological
disorders, such as drug metabolism other enzymes). Of note, it is
known that necessity of cytoskeletal modulation play a role in the
processes of nervous system development (Ramocki and Zoghbi,
2008). Additionally, neuroactive ligand receptor interaction path-
way was reported to be associated with substance addiction, which
is commonly observed comorbid condition in BPD patients (Li
et al., 2005).
The miRNA regulation potentially contributes to the functions
of these associated pathways in BPD. Recent findings exhibited
the essential roles of miRNA machinery in many aspects of ner-
vous system, including Dicer and miR-124 in neuronal develop-
ment and miR-134 in synaptic development (Gao, 2008; Saba
and Schratt, 2010). Regulation of calcium channel gene expres-
sion by miR-103 was also reported (Favereaux et al., 2011). In
addition to enriched GO and KEGG pathways, we also identi-
fied many significant pathways that were obtained from curated
data in the literature in MsigDB, which was mainly based on gene
expression studies related with multiple cancers. Examining the
functions of miRNA-associated genes in these enriched pathways
suggested the involvement of different miRNA regulation in the
etiology of BPD, including Notch signaling (e.g., JAG1), axonal
growth, and guidance (e.g., CNTN4, NFIB, NAV3, and PTPRD),
and cholesterol homeostasis (e.g., ABCA1) (Hekimi and Kershaw,
1993; Bixby, 2000; Karasinska et al., 2009; Mason et al., 2009; Shi-
moda and Watanbbe, 2009; Pedroso et al., 2012). In addition,
our identified BPD-associated pathways consisted of many col-
lagen related genes, such as COL1A2, COL27A1, and COL5A1,
implicating that these genes may augment their impacts on BPD
through miRNA regulation. Although the connection of collagen
and BPD was rarely reported in the literature, the emerging data
and evidence, came from in vivo studies suggested that collagen
joined the processes of axonal growth and guidance, synaptoge-
nesis, and Schwann cell myelination during the development of
nervous system (Hubert et al., 2009).
Among these identified miTGs (in Table 4), some of them have
been previously linked to the regulation of miRNA machinery.
A recent study showed the mediation of miR-34a and miR-21
on expression of JAG1, to regulate the differentiation of human
monocyte-derived dendritic cell, which is involved in five of our
identified curated gene sets (Hashimi et al., 2009). In addition,
increased expression of NAV3 mRNA was observed in brain tissue
of Alzheimer’s disease and was suggested to be regulated by miR-
29a (Shioya et al., 2010). On the contrary, the links between miR-
NAs and BPD were rarely constructed. Most of psychiatric- and
neurological-associated miRNAs used in this study were reported
to be related to schizophrenia, Alzheimer disease, autism, and
Parkinson disease (according to PhenomiR database). Future stud-
ies are also needed to uncover the impacts of these miRNAs on the
etiology of BPD.
There are some limitations in the present study. First, Pmin-
value was used to represent the significance level of a gene. The
information of other SNPs in a gene region may be missed.
Nevertheless, previous studies showed that using Pmin-value in
pathway analysis provides consistent results with other measures
of gene-level statistic (Torkamani et al., 2008; Baranzini et al.,
2009). Second, despite using more comprehensive pathway (e.g.,
MsigDB) and miRNA-disease/phenotype (e.g., PhenomiR) data-
bases, the incompleteness of annotated pathways and miRNA-
disease/phenotype information could have impacts on the cor-
rectness of the identified BPD-associated pathways. Third, the
target genes of psychiatric- and neurological-associated miRNAs
were predicted by computational methods. Although we used two
miRNA target prediction algorithms to increase the correctness
of prediction, further experimental validation by using functional
studies are still needed in the future.
In conclusion, with integrating currently known psychiatric-
and neurological-associated miRNAs as prior information, our
pathway-based analyses using the GWA dataset of BPD identified
not only previously reported pathways, but also new pathways that
showed intriguing biological plausibility for BPD. So far, miR-
NAs studies in BPD are still in the infant stage. Our findings
provided further evidence and support for exploring the roles of
miRNA regulation in relation to nervous system for the risk of
developing bipolar illness, especially ion channel regulation and
axonal development. More, investigations remain to be done to
elucidate the functions of these candidate pathways and genes,
and the potential mechanisms involved with miRNA-mediated
regulation.
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APPENDIX
Table A1 | Number of pathways at different cut-off in four statistical scenarios (total number of pathways=4051).
Significance criterion GSEA SUM
Non-weighted Weighted Non-weighted Weighted
Empirical P -value<0.01 267 269 353 675
FDRBH <0.01 48 40 140 363
GSEA, gene set enrichment analysis; SUM, sum-statistic approach; FDRBH, false discovery rate with control of multiple testing by using Benjamini & Hochberg’s
method.
Table A2 | Number of pathways identified by GSEA or SUM methods at significant level of 0.01 under weighted and non-weighted schemes
(total number of pathways=4051).
Non-weighted Weighted
GSEA SUM
≥0.01 <0.01 ≥0.01 <0.01
Empirical P -value ≥0.01 3685 99 3374 324
<0.01 97 170 2 351
FDRBH ≥0.01 3983 20 3688 223
<0.01 28 20 0 140
FDRBH, false discovery rate with control of multiple testing by using Benjamini & Hochberg’s method.
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